- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Hongbin Zou
- Numer telefonu: +8618040026871
- E-mail: hongbinzou300@gmail.com
Lokalizacje studiów
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chiny, 150085
- Jeszcze nie rekrutacja
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Dongfeng He
- Numer telefonu: 18040026871
- E-mail: 2919534184@qq.com
-
-
Jilin
-
Yanji, Jilin, Chiny, 133000
- Rekrutacyjny
- Yanbian University Hospital
-
Kontakt:
- Songnan Zhang
- Numer telefonu: 18040026871
- E-mail: 2919534184@qq.com
-
-
Liaoning
-
Shenyang, Liaoning, Chiny, 110000
- Aktywny, nie rekrutujący
- The First Hospital of China Medical University
-
Shenyang, Liaoning, Chiny, 110001
- Jeszcze nie rekrutacja
- Liaoning Cancer Hospital
-
Kontakt:
- Wenheng Zheng
- Numer telefonu: 18040026871
- E-mail: 2919534184@qq.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);
- Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;
- Liver function at Child-Pugh grade A or B (≤ 7 points), ECOG PS 0-1;
- Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;
Exclusion Criteria:
- Severe liver dysfunction: Child-Pugh C grade (≥ 8 points) or active hepatic encephalopathy Illness;
- Extensive extrahepatic metastases (e.g., lung, bone, or peritoneum metastases);
- Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;
- Renal failure: Creatinine clearance rate < 30 mL/min;
- Thrombocytopenia (less than 50×10⁹/L) or coagulation dysfunction (INR greater than 1.5);
- Active infection (such as uncontrolled hepatitis B virus replication with HBV-DNA > 2000 IU/mL);
- ECOG PS ≥ 2 or extremely poor overall condition;
- Diabetic patients with acute ketoacidosis or during the period of severe infection;
- Pregnant and lactating women;
- Known history of other malignancy.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Epalrestat plus HAIC, donafenib and tislelizumab
Epalrestat 50mg tid, donafenib 0.2g bid, tislelizumab 200mg per 21days, HAIC (FOLFOX or RALOX) per 21days |
For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day. donafenib 0.2g BID, tislelizumab 200mg/21days Include FOLFOX and RALOX.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
12-month Event-free survival (EFS) Rate
Ramy czasowe: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
The proportion of patients who have remained event-free from the start of treatment until the 12-month time point.(Predefined events include: progression of disease, death for any reason, terminate the treatment due to intolerable AEs.) |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Event-free survival (EFS)
Ramy czasowe: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Defined as the time from treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs). |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
|
Overall survival (OS)
Ramy czasowe: Up to approximately 2 years
|
The OS is defined as the time from the enrollment to death due to any cause. |
Up to approximately 2 years
|
|
Progression free survival(PFS) (Overall)
Ramy czasowe: From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first. |
From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of intra-hepatic lesions
Ramy czasowe: From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of extra-hepatic lesions
Ramy czasowe: From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Objective response rate(ORR) per RESCIST 1.1
Ramy czasowe: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1. |
Up to approximately 2 years
|
|
ORR per mRECIST
Ramy czasowe: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST. |
Up to approximately 2 years
|
|
PVTT response rate per mRECIST
Ramy czasowe: Up to approximately 2 years
|
The PVTT response rate is defined as the proportion of patients with a documented CR or PR of PVTT. According to the Vp classification: CR: PVTT disappears or the portal vein becomes completely unobstructed. PR: Decrease in VP classification. SD: Without PR and PD. PD: Increase in VP classification. |
Up to approximately 2 years
|
|
Disease control rate(DCR) per RESCIST 1.1
Ramy czasowe: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per RECIST 1.1. |
Up to approximately 2 years
|
|
DCR per mRECIST
Ramy czasowe: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per mRECIST. |
Up to approximately 2 years
|
|
Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
Ramy czasowe: Up to approximately 2 years
|
The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0. |
Up to approximately 2 years
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Haibo Shao, First Hospital of China Medical University
- Główny śledczy: Tao Han, First Hospital of China Medical University
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby metaboliczne
- Nowotwory według typu histologicznego
- Nowotwory Układu Pokarmowego
- Choroby Układu Pokarmowego
- Zaburzenia metabolizmu glukozy
- Choroby wątroby
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Nowotwory wątroby
- Rak
- Choroby żywieniowe i metaboliczne
- Rak wątrobowokomórkowy
- Cukrzyca
- Tislilizumab
- Donafenib
- epalrestat
Inne numery identyfikacyjne badania
- kelunshen【2025】2025-861-2
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Consent and privacy: Participants usually only agreed to data use in the original study. Sharing IPD may violate that agreement. And we want to protect our academic credit and avoid misuse of the data.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .